PT-141 (Bremelanotide)
Bremelanotide (PT-141) is FDA-approved as Vyleesi for a specific medical indication.
What it is
PT-141, or bremelanotide, is a melanocortin-receptor agonist and one of the genuine FDA-approved drugs in this library: it is sold as Vyleesi, approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
That approval rests on controlled trials with characterized side effects — nausea being the most common. The gray market sells PT-141 far beyond the approved indication, mostly to men, a use the approval evidence does not cover.
What researchers have actually studied it for
Hypoactive sexual desire disorder in premenopausal women — its FDA-approved indication — plus earlier erectile-function research.
How it works
Bremelanotide activates melanocortin receptors (chiefly MC4R) in brain circuits involved in sexual desire — a central-nervous-system mechanism, unlike the blood-flow route of PDE5 drugs. It descends chemically from melanotan II, with the pigmentation activity dialed down but not to zero.
The molecule itself
Bremelanotide — a cyclic heptapeptide melanocortin agonist, a ring-closed analog of alpha-MSH with strongest activity at MC4R (desire circuitry) and meaningful MC1R activity (pigmentation — the heritage that occasionally darkens skin with frequent use). The cyclization confers stability the linear parent lacks.
Where it came from
Its origin story is pharmacology folklore: University of Arizona tanning-peptide research in the 1990s produced unexpected sexual side effects, spinning out both melanotan II's gray-market career and bremelanotide's legitimate one. After an intranasal blood-pressure setback and reformulation, FDA approval came in 2019.
The timeline
1990s
University of Arizona tanning-peptide research observes the famous sexual side effects.
2000s
Intranasal development for erectile dysfunction halts over blood-pressure findings.
2010s
Reformulated as subcutaneous autoinjector; RECONNECT phase 3 in HSDD.
2019
FDA approves Vyleesi for premenopausal HSDD.
2020s
Gray-market male/couples market grows outside the approval.
What the research record actually contains
- RECONNECT phase 3 trials: statistically significant desire and distress improvements versus placebo in the approved population.
- Earlier erectile-function studies (male use) that were not carried to approval.
- Post-market experience since 2019 within the approved indication.
What could change this assessment
The melanocortin field around it is expanding (setmelanotide's rare-obesity franchise, inflammation programs), which will keep the receptor family in the news. For PT-141 itself, watch real-world-use data within the approval — and the regulatory attention its gray market is courting.
What's known about risks
Trial-documented: nausea in roughly 40% of users (the headline tolerability issue), flushing, headache, transient blood-pressure rises (contraindicated in uncontrolled hypertension), and focal skin darkening with frequent use — the melanocortin heritage showing through.
Where it stands legally
Prescription drug (Vyleesi) for its approved indication; anything outside that — including the male-market vials online — is either off-label medicine (prescriber territory) or unregulated gray market (no one's territory).
Worth asking a licensed provider
- 1.Does my situation match the approved indication, or would this be off-label?
- 2.Is my blood pressure compatible with a melanocortin agonist?
- 3.What non-drug and established-drug options should we consider first?
Common claims, corrected
“It's female Viagra.”
Reality: Wrong mechanism and wrong moment: PDE5 drugs act on blood flow during arousal; bremelanotide acts on brain desire circuits hours ahead. The nickname misdescribes both drugs.
“The male versions online are the same medicine.”
Reality: Male use was studied and abandoned pre-approval, partly on blood-pressure grounds; unscreened vials resurrect exactly the use case development rejected.
PT-141 (Bremelanotide) FAQ
Is PT-141 FDA-approved?
Yes — as Vyleesi, for a specific indication in premenopausal women. Uses outside that indication, including the male-market versions sold online, sit outside the approval and its evidence.
How is PT-141 different from Viagra-type drugs?
PDE5 inhibitors act on blood flow; PT-141 acts on melanocortin receptors in the nervous system — desire circuitry rather than vascular mechanics. Different mechanism, different evidence base, different risks.
What are PT-141's side effects?
In trials: nausea (common), flushing, headache, and blood-pressure effects that led to specific label warnings. A prescriber screens for the conditions that make it inappropriate.
Why does PT-141 cause nausea so often?
MC4R circuits sit near brainstem nausea circuits — roughly 40% of trial users reported it, making tolerability the drug's main negotiation. Trials managed it with usage limits the gray market ignores.
Can PT-141 darken skin?
Its residual MC1R activity can cause focal darkening with frequent use — the tanning-research heritage showing through, and one reason usage frequency is capped on the label.